The impact of dual bronchodilation on cardiovascular serious adverse events and mortality in COPD: a quantitative synthesis [Corrigendum]
Rogliani P, Matera MG, Ora J, Cazzola M, Calzetta L. International Journal of Chronic Obstructive Pulmonary Disease. 2017; 12:3469—3485. Page 3481, right column, last paragraph, line 3, the text “(fromoterol and indacaterol)” should read “(formoterol...
Main Authors: | Rogliani P, Matera MG, Ora J, Cazzola M, Calzetta L |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2018-10-01
|
Series: | International Journal of COPD |
Online Access: | https://www.dovepress.com/corrigendum-the-impact-of-dual-bronchodilation-on-cardiovascular-peer-reviewed-article-COPD |
Similar Items
-
Comparative studies of dual bronchodilation in COPD
by: Mario Cazzola, et al.
Published: (2021-02-01) -
Beyond Dual Bronchodilation – Triple Therapy, When and Why
by: Cazzola M, et al.
Published: (2022-01-01) -
Differential pharmacology and clinical utility of long-acting bronchodilators in COPD – focus on olodaterol
by: Matera MG, et al.
Published: (2015-12-01) -
The future of bronchodilation: looking for new classes of bronchodilators
by: Mario Cazzola, et al.
Published: (2019-12-01) -
LABA/LAMA combination in COPD: a meta-analysis on the duration of treatment
by: Luigino Calzetta, et al.
Published: (2017-01-01)